ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

ZYME Company Profile and Key Details

NYSE : ZYME

Zymeworks Inc.

$9.44

-0.56-5.60%

At Close 4:00 PM

60.77

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

ZYME Stock Price Chart

Stock Price Today

Zymeworks Inc. (ZYME) stock declined over -5.60%, trading at $9.44 on NYSE, down from the previous close of $10.00. The stock opened at $9.61, fluctuating between $9.04 and $9.68 in the recent session.

Stock Snapshot

Prev. Close

9.61

Open

656.81M

Market Cap

69.58M

Number of Shares

9.04

Day Low

9.68

Day High

-5.83

P/E Ratio

96.72%

Free Float in %

-1.62

EPS (TTM)

6.56

Book Value

-1.73

Cash Flow per Share

1.23M

Volume

Relevant Articles

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 10, 2025	9.61	9.80	9.03	9.44	1.24M
Apr 09, 2025	9.52	10.24	9.22	10.00	2.24M
Apr 08, 2025	11.06	11.10	9.74	9.91	941.29K
Apr 07, 2025	10.15	10.75	9.71	10.43	1.19M
Apr 04, 2025	11.40	11.75	10.61	10.95	1.16M
Apr 03, 2025	11.57	12.08	11.54	11.75	1.1M
Apr 02, 2025	11.73	12.01	11.44	11.92	523.07K
Apr 01, 2025	11.81	12.05	11.49	11.62	655.81K
Mar 31, 2025	12.07	12.10	11.52	11.91	577.42K
Mar 28, 2025	12.59	12.64	12.20	12.37	320.35K
Mar 27, 2025	12.31	12.71	12.16	12.51	317.2K
Mar 26, 2025	12.75	12.75	12.15	12.35	654.5K
Mar 25, 2025	13.19	13.28	12.67	12.80	647.05K
Mar 24, 2025	12.88	13.21	12.80	13.05	526.33K
Mar 21, 2025	12.80	13.03	12.64	12.72	800.63K
Mar 20, 2025	12.86	13.00	12.64	12.93	697.5K
Mar 19, 2025	12.36	12.80	12.09	12.79	592.95K
Mar 18, 2025	12.65	12.97	12.11	12.34	664.29K
Mar 17, 2025	12.23	12.65	11.85	12.58	667.11K
Mar 14, 2025	12.96	13.17	12.23	12.25	577.8K

Contact Details

Vancouver, BC V5T 1G4

Canada

Website: https://www.zymeworks.comContact: 160 467 81388

About Company

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Frequently Asked Questions

What is the current Zymeworks Inc. (ZYME) stock price?

Zymeworks Inc. (NYSE: ZYME) stock price is $9.44 in the last trading session. During the trading session, ZYME stock reached the peak price of $9.68 while $9.04 was the lowest point it dropped to. The percentage change in ZYME stock occurred in the recent session was -5.6% while the dollar amount for the price change in ZYME stock was -$0.56.

ZYME's industry and sector of operation?

The NYSE listed ZYME is part of Biotechnology industry that operates in the broader Healthcare sector. Zymeworks Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ZYME?

Dr. Ali Tehrani Ph.D.
Advisor
Dr. Ryan Dercho Ph.D.
Senior Director of Corporation Affairs
Nina Weisser Ph.D.
Director of Multispecific Antibody Therapeutics
Dr. Paul Moore Ph.D.
Chief Scientific Officer
Dr. Christopher Astle Ph.D.
Senior Vice President & Chief Financial Officer
Mr. Neil A. Klompas C.A., CPA, CA, CPA
Pres & Chief Operating Officer
Dr. Neil Josephson M.D.
Chief Medical Officer
Jack W. Spinks
Associate Director of Investor Relations
Mr. Kenneth H. Galbraith C.A.
Chief Executive Officer & Chairman
Dr. David Poon Ph.D.
Vice President of Bus. Devel. and Alliance Management
Diana Papove
Senior Mang. of Corporation Communications
Dr. Jeffrey Smith M.D.
Senior Vice President of Early-Stage Devel.
Mr. Mark Hollywood
Executive Vice President and Head of Technical & Manufacturing Operations
Mr. Daniel Dex J.D., Ph.D.
Senior Vice President, Corporation Sec. & Gen. Counsel
Ms. Laura O'Connor
Executive Director & Head of Global HR
Ms. Bijal Desai M.B.A.
Executive Director of Corporation Fin., FP&A & Procurement
Mr. Neil A. Klompas C.A., C.P.A., CA, CPA
Pres & Chief Operating Officer

How ZYME did perform over past 52-week?

ZYME's closing price is 18.44% higher than its 52-week low of $7.97 where as its distance from 52-week high of $17.70 is -46.67%.

How many employees does ZYME have?

Number of ZYME employees currently stands at 280.

Link for ZYME official website?

Official Website of ZYME is: https://www.zymeworks.com

How do I contact ZYME?

ZYME could be contacted at phone 160 467 81388 and can also be accessed through its website. ZYME operates from 114 East 4th Avenue, Vancouver, BC V5T 1G4, Canada.

How many shares of ZYME are traded daily?

ZYME stock volume for the day was 1.23M shares. The average number of ZYME shares traded daily for last 3 months was 592.54K.

What is the market cap of ZYME currently?

The market value of ZYME currently stands at $656.81M with its latest stock price at $9.44 and 69.58M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	280
Beta	1.13
Sales or Revenue	$76.01M
5Y Sales Change%	-0.396%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology